June 19, 2020 / 8:17 AM / 24 days ago

S.Korea's SK Biopharmaceuticals to raise $794 mln in IPO

SEOUL, June 19 (Reuters) - SK Biopharmaceuticals Co Ltd, the developer of a U.S.-approved anti-epileptic drug, said on Friday it had priced its initial public offering at the top of its indicative range to raise 959 billion won ($793.9 million) in an IPO expected in July.

The drugmaker’s shares priced at 49,000 won compared to a range of 36,000-49,000 won per share it announced in a regulatory filing earlier this month. ($1 = 1,207.9000 won) (Reporting by Joyce Lee; Editing by Jan Harvey)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below